This 2018 randomized controlled trial evaluated sexual adverse events in 117 men aged 23–50 receiving dutasteride 0.5 mg daily for androgenetic alopecia. During the 24-week double-blind phase, sexual adverse events (impotence, decreased libido, ejaculation disorders) occurred in 16% of the dutasteride group versus 8% in the placebo group. In the
